ASCO GU 2019

ASCO GU 2019: Alterations in DNA Damage Repair Genes and Outcomes to Systemic Therapy in 225 Immune-oncology versus Tyrosine Kinase Inhibitor Treated Metastatic Clear Cell Renal Cell Carcinoma Patients

San Francisco, CA (UroToday.com) During the Rapid Abstract Session C: Renal Cell Cancer at the Annual ASCO GU 2019 meeting in San Francisco, CA, Dr. Ged, presented on Alterations in DNA damage repair (DDR) genes and outcomes to systemic therapy in 225 immune-oncology (IO) versus tyrosine kinase inhibitor (TKI) treated metastatic clear cell renal cell carcinoma (mccRCC), patients.

ASCO GU 2019: Analysis of Overall Survival Based on Early Tumor Shrinkage in the Phase III METEOR Study of Cabozantinib versus Everolimus in Advanced Renal Cell Carcinoma

San Francisco, CA (UroToday.com) During the Rapid Abstract Session on Renal Cell Cancer at the Annual ASCO GU 2019 meeting in San Francisco, CA, Dr. Duran presented on the analysis of overall survival (OS) based on early tumor shrinkage in the phase III METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC).

ASCO GU 2019: Genetic Evolution of Metastatic Renal Cell Cancer

San Francisco, CA (UroToday.com) Dr. Samra Turajlic provided a summary of the genetic evolution of metastatic renal cell carcinoma, based on the work her research group is doing which was recently published. Renal cell carcinoma (RCC) is a highly polymorphic malignancy – as all clinicians know, there is significant variability in terms of presentation, progression and prognosis. Often, this is insufficiently captured with current clinical staging and histology. 

ASCO GU 2019: Results of a Phase II Study of Atezolizumab and Bevacizumab in Non-clear Cell Renal Cell Carcinoma and Clear Cell Renal Cell Carcinoma with Sarcomatoid Differentiation

San Francisco, CA (UroToday.com) During the Rapid Abstract Session on Renal Cell Cancer at the Annual ASCO GU 2019 meeting in San Francisco, CA, Dr. McKay presented the results of a phase II study of atezolizumab and bevacizumab in non-clear cell renal cell carcinoma (nccRCC) and clear cell renal cell carcinoma with sarcomatoid differentiation (sccRCC).

ASCO GU 2019: Thirty Month Follow-up of the Phase III CheckMate 214 Trial of First-line Nivolumab + Ipilimumab or Sunitinib in Patients with Advanced Renal Cell Carcinoma

San Francisco, CA (UroToday.com) During the Rapid Abstract Session C: Renal Cell Cancer at the Annual ASCO GU 2019 meeting in San Francisco, CA, Dr. Tannir presented the much-awaited thirty-month follow-up data of the phase III CheckMate 214 trial of first-line Nivolumab combined with Ipilimumab (N+I) or sunitinib (S) in patients with advanced renal cell carcinoma (aRCC). N+I has shown superior OS v S in intention to treat (ITT) (IMDC any risk) and intermediate/poor-risk (I/P) patients with aRCC in CheckMate 214 at 17.5 month minimum follow-up. This led to N+I approval for first-line treatment of I/P aRCC patients.

ASCO GU 2019: First-Line Systemic Therapy in the Patient With Intermediate-or Poor-Risk Disease: What Agent Should It be in 2019?

San Francisco, CA (UroToday.com) According to the latest update form the Checkmate 214 study, published in 20181, in intermediate and poor risk patients the combination of nivolumab +ipilimumab has an objective response rate of 42% compared to 27% in the sunitinib group, with a complete response rate of 9% vs. 1%. The hazard ratio (HR) for PFS was 0.82 (95% CI 0.63-1.05), with a median overall survival that was not reached with nivolumab +ipilimumab, and a HR of 0.63 (0.44-0.89). These data resulted in the approval of Nivolumab+ ipilimumab as standard of care treatment for intermediate and poor risk patients on April 2018. In favorable risk group the objective response rate was 29% for nivolumab vs. 52% for sunitinib, as can be seen in table 1.

ASCO GU 2019: TIVO-3: Tivozanib Compared to Sorafenib in Patients with Refractory Advanced Renal Cell Carcinoma (RCC)

San Francisco, CA (UroToday.com) Dr. Rini presented the preliminary results of the TIVO-3 trial, which is a phase 3 randomized controlled multi-center, open-label study to compare Tivozanib (TIVO)  to sorafenib in patients with refractory advanced renal cell carcinoma (RCC) (Clinical trial information: NCT02627963). TIVO is a potent, selective inhibitor of VEGFR 1,2,3 with a long half-life designed to optimize VEGFR blockade and minimize off-target toxicities.
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe